Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous bapineuzumab in APOE ε4 non-carriers with mild to moderate Alzheimer's disease
2009-012748-17Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bapineuzumab IV with Placebo IV (2 arms). Primary endpoints: ADAS-Cog and DAD. Started Jun 2009; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-012748-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012748-17.